Mumbai, Oct. 28 -- Revenue from operations increased 28% year on year to Rs 2,617 crore from Rs 2,044 crore.

EBITDA climbed 72% year on year to Rs 385 crore from Rs 224 crore. The company said EBITDA margin expanded by 370 basis points to 14.7% in Q2 FY27, supported by higher capacity utilisation, operating leverage, disciplined execution and cost optimisation.

Pre-tax profit stood at Rs 82 crore in Q2 FY27, compared with a loss of Rs 46 crore in Q2 FY26.

Material costs rose 29% to Rs 906 crore from Rs 703 crore, while employee expenses increased 17% to Rs 714 crore from Rs 611 crore. Other expenses climbed 13% to Rs 648 crore from Rs 571 crore.

Piramal Pharma added 22 new customers and completed 12 regulatory inspections and 110 cust...